As part of our expert series on the state of the industry, OneMedRadio spoke with Glysure CEO Chris Jones to discuss this recent news and learn about this unique technology. Jones also discussed trends in the industry affecting company growth and investment strategy, including reimbursement issues, evolving exit strategy, and the move away from normative medicine.
GlySure Limited, developer of in-hospital continuous blood glucose monitoring systems, today announced that it has achieved ISO 13485 certification, the global standard for the requirements of a quality management system for the design, manufacture and distribution of medical devices. By establishing a quality management system that meets international regulatory and customer requirements, GlySure has set the foundation for its European clinical trials.
GlySure has developed an intravascular sensor capable of continuously monitoring a patient’s glucose for the length of their stay in the ICU.
GlySure’s technology enables a healthcare facility to implement tight glycemic control and intensive insulin therapy.
Advances in molecular biology now make it possible to detect diseases sooner, allowing physicians to advise patients on optimal therapies. “Global Molecular Diagnostics Market: Opportunities & Future Forecast” reports that based on its exceptional ability to accurately detect the primary cause of disease, molecular diagnostics has emerged as the fastest growing segment of the in vitro diagnostics (IVD) industry.
Copyright © 2024 | WordPress Theme by MH Themes